NEW YORK, January 26, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on NVAX, OPK, OTIC, and PBYI which can be accessed for free by signing up to http://www.wallstequities.com/registration. On Thursday, January 25, 2018, the NASDAQ Composite ended
Gaithersburg, Maryland headquartered Novavax Inc.'s stock finished Thursday's session 3.18% lower at $2.13 with a total trading volume of 9.03 million shares. The Company's shares have advanced 83.62% in the last month, 106.80% in the previous three months, and 56.62% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 47.57% and 84.14%, respectively. Additionally, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have a Relative Strength Index (RSI) of 64.77.
On January 05th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $2.25 per share. Get the full research report on NVAX for free by clicking below at:
On Thursday, shares in Miami, Florida headquartered Opko Health Inc. recorded a trading volume of 6.12 million shares, which was above its three months average of 4.59 million shares. The stock ended the session 3.09% higher at $5.00. The Company's shares have advanced 1.63% in the last month. The stock is trading above its 50-day moving average by 1.13%. Moreover, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 55.46. Today's complimentary research report on OPK is accessible at:
San Diego, California headquartered Otonomy Inc.'s shares closed the day 0.84% lower at $5.90. The stock recorded a trading volume of 252,525 shares. The Company's shares have gained 15.69% in the last month and 76.12% over the previous three months. The stock is trading above its 50-day moving average by 9.22%. Additionally, shares of Otonomy, which focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the US, have an RSI of 59.16. Register now for your free research document on OTIC at:
Shares in Los Angeles, California headquartered Puma Biotechnology Inc. finished 5.26% higher at $68.10. The stock recorded a trading volume of 2.74 million shares, which was above its three months average volume of 905.36 thousand shares. The Company's shares have advanced 103.59% over the last twelve months. The stock is trading below its 50-day moving average by 30.45%. Furthermore, shares of Puma Biotechnology, which focuses on the development and commercialization of products to improve cancer care, have an RSI of 28.89. Click on the link below and see our free report PBYI at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All